We study the molecular mechanisms underlying pediatric leukemia development and progression to identify novel vulnerabilities of childhood cancers. Using an array of cutting-edge technologies and state-of-the-art methods, we unveil how genetic mutations contribute to cancer development and investigate innovative therapeutic strategies to exploit them as potential drug targets in pediatric leukemia.  

Leukemia-associated oncoproteins frequently arise from mutations in genes that encode transcription factors and epigenetic regulators. We believe that the transforming properties of oncogenic proteins in leukemia are hard-wired in specific networks of physical, genetic, and epigenetic interactions with key effector genes and proteins. Functional exploration of these oncogenic signaling networks provides new insights into cellular pathways that are hijacked by leukemia drivers during disease development and maintenance. In our lab, we study cellular and molecular effects of leukemia oncoproteins through the development and use of advanced tools and approaches, including transcriptomics, proteomics, functional genomics, and high-resolution imaging.

Grebien Group at St. Anna CCRI: https://ccri.at/research-group/grebien-group/
Grebien Group at CeMM: https://cemm.at/research/groups/adjunct-groups/florian-grebien/research
Grebien lab webpage: https://grebienlab.com